参苓白术散加味治疗高脂血症68例

Clinical Observation of Sixty-eight Patients with Hyperlipidemia Treated by Shenling Baizhu Powder

目的:观察参苓白术散加味治疗高脂血症的临床疗效及安全性。方法:将136例高脂血症患者随机分为治疗组(68例)和对照组(68例)。治疗组给予参苓白术散加味治疗,对照组给予西药辛伐他汀片治疗,两组连续治疗8周,检测治疗前后两组患者临床疗效、血脂水平、血液流变学变化和不良反应。结果:1总有效率治疗组86.8%,对照组83.8%。两组比较无显著性差异。2中医证候疗效总有效率治疗组为89.7%,对照组为54.4%,两组比较有非常显著性意义(P<0.01)。3两组疗后总胆固醇(TC),甘油三酯(TG),高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白胆固醇(LDL-C)较疗前有非常显著或显著改变(P<0.01,P<0.05);治疗组降低TG[治疗后治疗组与对照组分别为(1.86±0.51),(2.54±0.69)mmol·L-1],升高HDL-C[治疗组与对照组分别为(1.74±0.52),(1.19±0.40)mmol·L-1]作用优于对照组(P<0.05)。4两组疗后全血黏度高切、全血黏度低切、血浆黏度和红细胞压积较疗前有显著降低(P<0.05),两组比较无显著性差异。5治疗组未见不良反应。结论:参苓白术散加味治疗高脂血症总有效率与辛伐他汀相当,降低TG和升高HDL-C优于对照组,能缓解患者中医证候,同时改善患者血液流变学,且无明显的不良反应。

Objective： The study aimed to observe the clinical efficacy and safety of Shenling Baizhu powder on patients with hyperl^pidemia. Method： In this study, 136 patients with hyperlipidemia were randomly divided into the treatment group （ referred to as Shenling Baizhu powder treatment） and the control group （referred to as the western medicine simvastatin treatment） with 68 patients in each group. Each group was treated for 8 weeks, and the clinical effect, lipid changes, blood rheology changes and side-effects before and after treatment were observed. Result： ① The total effective rate of the treatment group was 86. 8% , while it was 83.8% in the control group. With no significant difference. ② The total effective rate of traditional Chinese medicine （TCM） syndrome in treatment group was 89.7% , while it was 54.4% in control group, with significant difference between two groups （P 〈 0.01 ）. ③There were significant change in the total cholesterol （TC） , triglyceride （TG） , high density lipoprotein cholesterol （HDL-C） and low density lipoprotein cholesterol （LDL-C） between the two groups after treatment （P 〈 0.01, P 〈 0. 05）. The effects of reducing TG in the treatment group C the treatment group was （1.86±.51） mol.·L^-1, and the control group was （2.54±0.69） mmol·L^-1 and elevating HDL-C [The treatment group was （ 1.74±0.52）, and the control group was （ 1.19 ±0.40） mmol·L^-1 J were better than those in control group after treatment （P 〈 0.05）. ④ In the two groups, the whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and erythrocyte deposited were all had significantly lower than before treatment （P 〈 0.05） , but with no significant difference between the two groups. ⑤No side-effects were observed in treatment group. Conclusion： The total effective rate of Shenling Baizhu powder is equivalent to simvastatin in treating hyperlipidemia, but better than control group in reducing TG and elevating HDL-C is, which can alleviate the syndromes of patients, improve the blood rheology, with no side-effects.